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Background
Digital image analysis (DA) brings new opportunities to
enhance breast cancer pathology testing by providing
tools to read tissue-based visual data in a more precise,
accurate, and high-throughput manner compared to tra-
ditional evaluation performed by a pathologist. The
applications may vary from very practical computer-
assisted diagnosis approaches to obtain more reproduci-
ble estimates of biomarker expression to more sophisti-
cated efforts to retrieve and aggregate multi-modal and
multi-dimensional data providing integrated metamar-
kers of the disease [1,2].
Immunohistochemistry (IHC) biomarkers are widely
used for breast cancer categorization and provide basis
for therapeutic decisions [3], therefore, standardization
of IHC testing is of great importance. Applying DA
tools for post-analytical IHC phase generates continuous
data of broad dynamic range and can be used to analyse
variance of the biomarker expression in more powerful
statistical models and achieve better reproducibility.
Also, analytical phase of IHC testing may also benefit
from DA-based quality control systems. Another parti-
cular aspect of breast cancer diagnosis is related to
HER2 gene and protein assays where better quantifica-
tion systems are needed to resolve issues of tumours
with equivocal and discordant HER2 status, potentially
related to heterogeneity of tumour cell populations [4].
We hereby summarize our recent experiments to
explore the advantages of DA for breast cancer pathol-
ogy diagnosis and retrieval of new quality information
based on IHC and FISH tests: DA-based quality monitor
of tissue controls used for routine HER2 IHC testing,
feasibility of DA to obtain automated cell-based HER2
FISH data, and the potential of factor analysis of the
DA-generated IHC multi-marker expression data set to
understand breast cancer immunoprofile variation.
Materials and methods
For DA-based quality monitor, IHC tissue controls
represented by consecutive serial sections (n=91) of for-
malin-fixed paraffin-embedded multi-blocks containing
2 mm diameter cores from 4 different tumour samples
(HER2 IHC score 0, 1+, 2+, 3+) were used for routine
HER2 IHC staining (Ventana Benchmark XT, Ventana
Medical Systems, Tucson, Arizona, USA) one control
section per batch. The stained sections were scanned
(Aperio ScanScope XT at 20x objective magnification)
and submitted for routine quality review of the staff in
charge. DA (Aperio Genie and Membrane algorithms)
on each spot was performed on “per-batch” basis; the
control sections were then reviewed by a pathologist to
estimate potential HER2 staining intensity variation.
Batch-to-batch variation of IHC average membrane
staining intensity, number of tumour cells, and percen-
tage of tumour cells with complete membranous stain-
ing was examined and compared to the visual evaluation
results.
For automated HER2 FISH data, tissue microarray
(TMA) 4 μm-thick sections were stained with Vysis
HER2 FISH kit (as described previously [5]); 38 digital
images from 19 patients with ductal breast carcinoma
were obtained from TissueFAXS (TissueGnostics
GmbH, Vienna, Austria) using 63x oil objective and
extended focus option in 9 Z planes set at 0.45 μm
interval between the planes; the Z stack images were
then projected into 2D images. TissueQuest version 4
(TissueGnostics GmbH) DA with the DotFinder v.4
algorithm was used to detect the FISH signals. By using
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the gating feature of the TissueQuest software, analysis
was restricted to cell populations with non-overlapping
nuclei to obtain cell-based FISH results. Two observers
performed conventional microscope FISH analysis (40
cells per patient) according to Food and Drug Adminis-
tration scoring system. The same microscope and objec-
tive was used for the visual evaluation and digital image
acquisition.
Factor analysis of the DA-generated IHC multi-marker
expression data was performed on tissue microarrays
(TMA) of ductal carcinoma samples from 109 patients
stained for 10 IHC markers as recently reported [6].
Statistical analyses were performed with SAS 9.2
software.
Results and discussion
Digital analysis-based HER2 IHC quality monitor
DA performed on the IHC tissue multi-control sections
provided continuous output data that could be effi-
ciently summarized (Table 1) and visualized (Figure 1)
to reveal variation in the serial sections of tissue multi-
controls used in consecutive IHC batches. While linear
plot of the mean values (for all 4 tissue samples in the
multi-control) of the average membrane intensity and
percentage of cells with complete membranous staining,
indicated individual IHC batches with unexpected varia-
tion (Figure 1), the analyses performed on each multi-
control sample uncovered even greater variation (not
shown), potentially reflecting an impact of the variable
content of the control tissue in the serial sections. The
variation was not significantly related to neither the IHC
staining time (morning/afternoon/overnight run), nor
the weekday (by ANOVA, not shown). The pathologist’s
visual review of the controls mostly detected samples
with lower than expected IHC HER2 mean intensity
score (Table 1). Taking into account only 2+ and 3+ tis-
sue controls given a lower than expected intensity score,
only 3 IHC batches would have been considered as
“under-stained”. Interestingly, additional review of digital
images of the 2+ serial sections arranged consecutively
on computer monitor (Figure 2) revealed staining inten-
sity variation, in particular, increased intensity that was
missed by conventional microscope review but detected
by the DA. To explore possible “long-term” drifts of the
IHC sensitivity, we plotted intercepts of the parameters
(Figure 3) along the consecutive tests: a mild decrease of
the average membrane staining intensity was noted,
further supported by corresponding weak correlation
between the staining intensity and section number
(r=0.32, p<0.0001). Nevertheless, the mean percentage
of cells with complete membranous staining remained
stable.
The DA-based HER2 IHC quality monitor provided a
measurement of IHC staining quality useful in two
aspects: as a quality control tool to alert on unexpected
variation prospectively and as a quality improvement
measure disclosing potential assay drifts based on retro-
spective analysis of the data. Although the use of DA to
improve analytical phase of the IHC test has been sug-
gested [7], we were not able to find published data on
practical solutions. In our study, the DA parameters
analysed on “per batch” basis revealed a rather broad
IHC staining intensity variation underestimated by
microscope-based IHC quality control review, while
only a few cases with potential quality issues were
detected by additional retrospective pathologist’s review.
The application of DA for IHC quality monitor is not
as straightforward as it may appear. Several methodolo-
gical issues have to be considered with caution.
Although the same DA algorithm was used for the ser-
ies, the impact of the tissue variation does not allow for
a “pure” IHC tissue control system where, ideally, always
an identical tissue section would be used as a reference.
Although serial sections are expected to provide rather
continuous changes of the tissue properties, cutting and
other artefacts may impact the DA results. Furthermore,
in our experiment we used a sophisticated DA algo-
rithm, based on automated tumour tissue recognition,
which may be dependent on section thickness, hematox-
ylin staining variation, etc. For this matter, the use of
IHC multi-controls containing 4 different tumour sam-
ples could be regarded as an “internal control” for tis-
sue-related DA variation, however, further optimization
of the approach is needed.
Table 1 Digital image analysis outputs and pathologist’s IHC HER2 score on the IHC multi-block tissue controls
Core #1 HER2 0 Core #2 HER2 1+ Core #3 HER2 2+ Core #4 HER2 3+ Cores #1-4 Mean
Mean membrane intensity* 176 ± 16 190 ± 7 155 ± 11 86 ± 11 152 ± 8
% of cells with complete membranous staining* 1 ± 4 2 ± 5 17 ± 6 59 ± 6 19 ± 4
Total number of cells* 4277 ± 3205 6759 ± 3342 17536 ± 3382 19803 ± 4269 12094 ± 2778
Pathologist’s HER2 staining intensity score
corresponding the expected category**
87/88 73/89 88/91 84/87 N/A
* Mean ± standard deviation
** Data represented as a ratio of number of corresponding HER2 score/all cores evaluated. In all discordant cases, except in the category of Core#1 HER2 0,
pathologist gave a lower intensity score than that expected for the category. Total number of IHC control slides evaluated was 91, except some tissue cores were
considered inadequate by the pathologist (number of cores represented in the denominator).
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Automated HER2 FISH quantification
Strong correlation was observed between the numbers of
microscope- and DA-estimated HER2 and CEP17 signals/
cell (r=0.83, p<0.0001 and r=0.68, p<0.002, retrospec-
tively), and HER2/CEP17 ratio (r=0.71, p=0/0006); the
corresponding correlations between two microscope eva-
luations was close to perfect. However, ANOVA analysis
revealed significant bias to lower values of the DA-
counted HER2 signals when compared to the microscope
evaluation (average difference 1.35, CI 0.4-2.3, p<0.05).
Meanwhile, no significant difference was observed
between the methods when comparing CEP17 signal
counts and HER2/CEP17 ratio.
We present our initial data on the DotFinder algorithm
to detect HER2 and CEP17 signals, which is followed by
other TissueQuest functionalities to select populations of
non-overlapping tumour cells in paraffin sections.
Although the final aim of the analysis is to achieve an
automated cell-based quantification of the FISH signals
providing a robust and high-throughput tool to investi-
gate tumour tissue heterogeneity, in this first stage of
validation, we have explored the accuracy of the signal
detection. One major obstacle to achieve full automation
of the analysis is related to spatial clustering of HER2 sig-
nals in some amplified cases; other algorithms (e.g., Auto-
Vysion, Metafer) switch to area-based estimate of the
“clusters” [8,9]. This latter approach is clinically valid to
detect amplified cases, however, to investigate intratu-
moral heterogeneity, a cell-based measurement providing
actual number of FISH signals would be preferable. In
our experiment, we did not include the “cluster” cases
detected by conventional microscope evaluation, never-
theless, underestimation of the HER2 (but not CEP17)
signal is likely to be related to spatial confluence of the
Figure 1 Variation of the intensity of HER2 membranous staining and the percentage of cells with complete membranous staining in
the consecutive tissue multi-control sections. Mean intensity of the average HER2 membranous stain and Mean percentage of cells with
complete membranous staining are represented by the orange and blue lines, respectively. The means are calculated from all 4 samples of the
tissue multi-control. Dashed orange and blue reference lines delineate the corresponding upper and lower quartiles.
Laurinavicius et al. Diagnostic Pathology 2013, 8(Suppl 1):S15
http://www.diagnosticpathology.org/content/8/S1/S15
Page 3 of 6
signals in some HER2-amplified cells. Since the images
for the analyses are produced by projecting 9 Z-stack
images into one, some information allowing better signal
discrimination is inevitably lost. We therefore suggest
that with the increase in computing and storage capacity,
3-dimensional FISH-detection algorithms may be the
basic way to progress further.
Factor analysis of the DA-generated IHC multi-marker
expression data
We have recently published [6] a study on breast cancer
TMA stained for 10 IHC markers proving a concept
that important biological interdependencies can be
detected at the level of tumour tissue immunophenotype
based on the factor analysis of DA data. This “auto-
mated readout” of the IHC data in the TMA revealed
independent biological processes standing behind the
IHC profile variability in the disease entities. Integral
characteristics (factor scores) of individual patients were
associated with main conventional categories of the
breast ductal carcinoma. In particular, we found that
major factor of the IHC profile variation was character-
ized by a strong inverse relation between the expression
of hormone (estrogen, progesteron, androgen) receptors
along with anti-apoptotic marker BCL2, on one side,
and Ki67 (proliferation) and HIF-1a (hypoxic stress,
angiogenesis) on the other side. We named this factor
the “i-Grade” since its pattern reflected the interdepen-
dent variance of the IHC markers known to represent
the axis from aggressive (Ki67, HIF-1a) to more indo-
lent (hormone receptor-positive, BCL2) behaviour of the
disease and was associated with the Nottingham histolo-
gical grade. Also, we were able to test independent
informative value of conventional and less explored IHC
biomarkers and their combinations.
Conclusions
In summary, we report on three DA approaches
expanding horizons of tissue-based breast cancer
research and clinical practice. We used standard IHC
Figure 2 Batch-to-batch variation of the mean staining intensity of HER2 can be noted visually on the consecutive tissue control
sections arranged on computer monitor. Nine consecutive HER2 IHC 2+ spot images are ordered from left to the right and down. Variable
brown colour intensity can be noted.
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and FISH techniques and commercially available DA
tools to retrieve new aspects of information that can be
used to enhance quality assurance and understanding of
breast cancer pathology.
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